ClinicalTrials.gg
CompletedNCT00990821Updated Aug 19, 2015Results posted

A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

A Phase 1 interventional study of 90 mg MK-0517 (PS80) and 100 mg MK-0517 (PS80) in Chemotherapy-Induced Nausea and Vomiting and Postoperative Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-19.

Primary conditionPostoperative Nausea and VomitingRegistry: VomitingReclassifiedWhy we changed it
Registry
Vomiting — the first condition term the registry derived for this study.
ClinicalTrials.gg
Postoperative Nausea and Vomiting
Why
  1. The study's listed conditions name Postoperative Nausea and Vomiting, a narrower term within Vomiting.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing aprepitant in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Aprepitant · Postoperative Nausea and Vomiting.

Enrollment
8th of 27
188 · median 115
Started
2005
the only one that year
Phase 1
2 of 27
none open now
Registered
8th of 27
by date
Lead sponsor
2 of 27
Merck Sharp & Dohme LLC

Among the 27 studies testing aprepitant in Postoperative Nausea and Vomiting, this one is the 8th largest by enrollment, is the only one that started in 2005, is one of 2 in phase 1, and was the 8th registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

2 of the 27 studies testing aprepitant in Postoperative Nausea and Vomiting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aprepitant

Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 65 Postoperative Nausea and Vomiting studies recruiting now, 22 (34%) set no upper age limit and 37 (57%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing aprepitant in Postoperative Nausea and Vomiting, or all of them as a file.
02

Study summary

This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults. Parts I to IV of this study will examine different doses of MK-0517 as well as two different formulations of MK-0517 (with and without polysorbate 80). Part V of the study will compare single doses of intravenous non-PS80 MK-0517 to oral 125-mg capsule of aprepitant. The primary hypothesis for Part V of the study is that a single intravenous dose of 100-mg or 115-mg MK-0517 is area under the plasma-time curve (AUC) equivalent to that of the 125-mg oral aprepitant capsule in young healthy participants.

03

Conditions studied

  • Chemotherapy-Induced Nausea and Vomiting
  • Postoperative Nausea and Vomiting

Browse trials for

04

In context

Postoperative Nausea and Vomiting Reclassified

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

This study's enrollment of 188 is above the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.

Browse Postoperative Nausea and Vomiting studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Postoperative Nausea and Vomiting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Vomiting. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is neither grossly overweight nor underweight for his/her height and body build
  • Subject is in good health -Subject is a nonsmoker
  • Subject is willing to avoid excessive alcohol consumption for the duration of the study
  • Subject is willing to avoid strenuous physical activity (i.e. unaccustomed weight lifting, running, bicycling) for the duration of the study
  • Subject agrees to refrain from consumption of grapefruit (and grapefruit products) before and during the study

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of multiple and/or severe allergies to drugs or food
  • Subject has donated blood or taken an drug in another clinical trial within the last 4 weeks
  • Subject has an infection, including (HIV) infection
  • Subject is a regular user of any illicit drug
  • Subject consumes excessive amounts of alcohol
  • Subject drinks excessive amounts of coffee, tea, cola or other caffeinated beverages
  • Subject currently uses on a regular basis, any prescription or non prescription medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Part I, Panel A

    100 mg MK-0517 (nonpolysorbate 80 formulation \[non-PS80\]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant

    Drug: 100 MK-0517 (PS80) + 2 mg midazolam · Drug: 100 mg MK-0517 (non-PS80) · Drug: 150 mg MK-0517 (Non-PS80) · Drug: Placebo · Drug: 125 mg Aprepitant

  • Experimental
    Part I, Panel B

    100 mg MK-0517 (PS80 formulation \[PS80\]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant

    Drug: 100 mg MK-0517 (PS80) · Drug: 150 mg MK-0517 (PS80) · Drug: Placebo · Drug: 125 mg Aprepitant

  • Experimental
    Part I, Panel C

    40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant

    Drug: 40 mg MK-0517 (non-PS80) · Drug: Placebo · Drug: 40 mg Aprepitant

  • Experimental
    Part II

    2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam

    Drug: 100 mg MK-0517 (PS80) · Drug: 2 mg Midazolam

  • Experimental
    Part III, Panel 1, Treatment Sequence 1

    125 mg aprepitant → 90 mg MK-0517 (PS80)

    Drug: 90 mg MK-0517 (PS80) · Drug: 40 mg MK-0517 (non-PS80) · Drug: 125 mg Aprepitant

  • Experimental
    Part III, Panel 1, Treatment Sequence 2

    40 mg MK-0517 (non-PS80) → 125 mg aprepitant

    Drug: 40 mg MK-0517 (non-PS80) · Drug: 125 mg Aprepitant

  • Experimental
    Part III, Panel 2

    40 mg MK-0517 (non-PS80)

    Drug: 40 mg MK-0517 (non-PS80)

  • Experimental
    Part IV

    40 mg MK-0517 (non-PS80 formulation)

    Drug: 40 mg MK-0517 (non-PS80)

  • Experimental
    Part V, Treatment Sequence 1

    125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)

    Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant

  • Experimental
    Part V, Treatment Sequence 2

    100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant

    Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant

  • Experimental
    Part V, Treatment Sequence 3

    115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)

    Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant

  • Experimental
    Part V, Treatment Sequence 4

    125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)

    Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant

  • Experimental
    Part V, Treatment Sequence 5

    100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)

    Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant

  • Experimental
    Part V, Treatment Sequence 6

    115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant

    Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant

Interventions

  • MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes

  • MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

  • Drug100 MK-0517 (PS80) + 2 mg midazolam

    MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.

  • MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

  • MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

  • MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.

  • MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.

  • MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.

  • DrugPlacebo

    Placebo matching MK-0517

  • Aprepitant, oral, tablet, single dose

  • Aprepitant oral tablet, single dose

  • Drug2 mg Midazolam

    Midazolam oral tablet, single dose

07

What researchers measure

Primary outcomes

  1. Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V

    AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. The AUC(0-inf) bioequivalence was evaluated for single doses of 100 and 115 mg MK-0517 PS80, IV and that of an oral 125-mg capsule of aprepitant. Period I to IV populations are not included in the outcome analysis because those were formulation and dose-finding/dose confirmation arms.

    Time frame: Up to 72 Hours Post Dose

08

Results

Posted Dec 12, 2013

Participant flow

One Investigator in the United States. Primary therapy period: 31-Jan-2005 to 01-Dec-2005.

Participant flow — Overall Study
MilestonePart I, Panel APart I, Panel BPart I, Panel CPart IIPart III, Panel 1, Treatment Sequence 1Part III, Panel 1, Treatment Sequence 2Part III, Panel 2Part IVPart V, Treatment Sequence 1Part V, Treatment Sequence 2Part V, Treatment Sequence 3Part V, Treatment Sequence 4Part V, Treatment Sequence 5Part V, Treatment Sequence 6
Started141614817171214121412141212
Completed1414148141411141213991011
Not completed02003310013521
Withdrew: Withdrawal by subject02003310013521

Outcome measures

PrimaryArea Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V

AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. The AUC(0-inf) bioequivalence was evaluated for single doses of 100 and 115 mg MK-0517 PS80, IV and that of an oral 125-mg capsule of aprepitant. Period I to IV populations are not included in the outcome analysis because those were formulation and dose-finding/dose confirmation arms.

Time frame:
Up to 72 Hours Post Dose
Reported as:
Least squares mean · ng*hr/mL
Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V
ng*hr/mLAprepitant (125 mg)MK-0517 (100 mg)MK-0517 (115 mg)
Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V29215 ± 1573124961 ± 1047731724 ± 14287

Adverse events

Collected over Up to 30 days after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
90 mg MK-0517 (PS80)—0/31 (0%)8/31 (25.8%)
100 mg MK-0517 (PS80)—0/82 (0%)8/82 (9.8%)
100 mg MK-0517 (PS80) + 2 mg Midazolam—0/8 (0%)5/8 (62.5%)
115 mg MK-0517 (PS80)—0/66 (0%)7/66 (10.6%)
150 mg MK-0517 (PS80)—0/12 (0%)3/12 (25%)
40 mg MK-0517 (Non-PS80)—0/36 (0%)4/36 (11.1%)
100 mg MK-0517 (Non-PS80)—0/12 (0%)3/12 (25%)
150 mg MK-0517 (Non-PS80)—0/11 (0%)6/11 (54.5%)
Placebo—0/11 (0%)2/11 (18.2%)
40 mg Aprepitant—0/14 (0%)2/14 (14.3%)
125 mg Aprepitant—0/133 (0%)6/133 (4.5%)
2 mg Midazolam—0/8 (0%)2/8 (25%)
Most frequent other events
Showing 10 of 16
Most frequent other events
Event90 mg MK-0517 (PS80)100 mg MK-0517 (PS80)100 mg MK-0517 (PS80) + 2 mg Midazolam115 mg MK-0517 (PS80)150 mg MK-0517 (PS80)40 mg MK-0517 (Non-PS80)100 mg MK-0517 (Non-PS80)150 mg MK-0517 (Non-PS80)Placebo40 mg Aprepitant125 mg Aprepitant2 mg Midazolam
SomnolenceNervous system disorders0/310/825/80/660/120/360/120/110/110/140/1332/8
TendernessGeneral disorders0/311/824/80/661/122/362/125/110/110/140/1330/8
HeadacheNervous system disorders6/310/820/82/662/120/360/123/112/110/145/1330/8
SwellingGeneral disorders0/310/820/80/660/121/360/123/110/110/140/1330/8
IndurationGeneral disorders0/310/821/80/660/123/362/122/110/110/140/1330/8
ErythemaSkin and subcutaneous tissue disorders0/310/821/80/660/123/362/122/110/110/140/1330/8
PainGeneral disorders0/310/820/80/660/122/362/120/110/110/140/1330/8
Infusion Site PainGeneral disorders0/317/821/85/660/121/361/121/110/110/140/1330/8
ContusionInjury, poisoning and procedural complications0/310/821/80/661/120/360/120/111/110/140/1330/8
Intraocular Pressure TestInvestigations0/310/820/80/661/120/360/120/110/110/140/1330/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part I, Panel APart I, Panel BPart I, Panel CPart IIPart III, Panel 1, Treatment Sequence 1Part III, Panel 1, Treatment Sequence 2Part III, Panel 2Part IVPart V, Treatment Sequence 1Part V, Treatment Sequence 2Part V, Treatment Sequence 3Part V, Treatment Sequence 4Part V, Treatment Sequence 5Part V, Treatment Sequence 6Total
Mean31.2 (21 to 45)35.2 (23 to 44)33.1 (22 to 45)36.9 (25 to 45)33.2 (19 to 43)33.2 (19 to 43)32.4 (18 to 45)29.4 (18 to 45)31.9 (19 to 44)33.5 (22 to 44)31.3 (22 to 45)29.1 (19 to 41)30.4 (19 to 45)36.5 (20 to 43)32.6 (18 to 45)
Sex: Female, Male
Sex: Female, Male(Participants)Part I, Panel APart I, Panel BPart I, Panel CPart IIPart III, Panel 1, Treatment Sequence 1Part III, Panel 1, Treatment Sequence 2Part III, Panel 2Part IVPart V, Treatment Sequence 1Part V, Treatment Sequence 2Part V, Treatment Sequence 3Part V, Treatment Sequence 4Part V, Treatment Sequence 5Part V, Treatment Sequence 6Total
Female79105111010107116646112
Male7743672453688676
09

Study locations

No study locations are listed for this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Dec 2005 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 8 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2009
First posted
Oct 7, 2009
Start
Jan 2005
Primary completionActual
Dec 2005
CompletionActual
Jan 2006
Results first posted
Dec 12, 2013
Last update
Aug 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00990821
Responsible party
Sponsor
First posted
Oct 7, 2009
Start date
Jan 2005
Primary completion
Dec 2005
Completion
Jan 2006
Results posted
Dec 12, 2013
Last update
Aug 19, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fosaprepitant · Aprepitant

Start the discussion